Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACtiVe trial of PheraLys-loaded autologous dendritic cells in resected pancreatic cancer
NL-OMON44379Phase 2Withdrawn
- Sponsor
- Erasmus MC
- Start
- Sep 2017
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MesoPher in pancreatic cancer (PC) and pancreatic adenocarcinoma (PDAC), sponsored by Erasmus MC. Primary endpoint: Feasibility of administering MesoPher after adjuvant standard-of-care therapy. Planned start Sep 2017; status: withdrawn.
02
Drugs
MesoPher
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON44379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44379.